アルツハイマー病患者の涙に含まれる診断バイオマーカーの同定: COG-EYE パイロット研究 (COG-EYE)
アルツハイマー病患者の診断によるバイオマルキュール診断の識別 : L'étude Pilote COG-EYE
The diagnosis of Alzheimer's disease (AD) relies on the detection of protein biomarkers, particularly in cerebrospinal fluid (e.g., Aβ and phosphorylated Tau) or through brain imaging. The invasive nature of lumbar puncture and the numerous contraindications have driven the search for early and reliable diagnostic biomarkers for AD.
Human tears are an accessible biological fluid that has proven relevant in the biomarker search strategy for both ophthalmological and systemic diseases, especially neurodegenerative conditions. Advances in methods for low-volume analysis have facilitated the identification of tear biomarkers. Total tau has been reported as elevated in the tears of patients with AD compared to controls (n=65). Additionally, metabo-lipidomic analyses offer several advantages (accessibility, non-invasiveness, reproducibility) and also appear promising as a diagnostic tool for systemic and neurodegenerative diseases, such as amyotrophic lateral sclerosis. This supports the relevance of comparing both AD proteins biomarkers and metabo-lipidomic signatures in the tears of patients with AD (Mild Cognitive Impairement (MCI) and dementia) with healthy controls.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Victoire LEROY, MD
- 電話番号:0247477693
- メール:victoire.leroy@univ-tours.fr
研究連絡先のバックアップ
- 名前:Raoul Kanav KHANNA, MD, PhD
- メール:raoul.khanna@univ-tours.fr
研究場所
-
-
France
-
Tours、France、フランス、37044
- 募集
- CHRU de Tours
-
主任研究者:
- Victoire LEROY, MD
-
コンタクト:
- Victoire LEROY
- 電話番号:+332 47 47 76 93
- メール:victoire.leroy@univ-tours.fr
-
コンタクト:
- Coralie TAILLEBUIS
- 電話番号:+332 47 47 39 09
- メール:cpcq@chu-tours.fr
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥18 years
- Participant affiliated in French Social Security scheme
- Informed and written consent from the participant
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Participant under judicial protection measures
- Participant under guardianship or curatorship
- Contraindications to participation in the research:
Other neurodegenerative disease Any eye drops or treatment that may interfere with tear production Occasional or permanent contact lens use within the last 3 months Eye surgery ≤3 months Any ocular pathology other than refractive errors, oculomotor disorders, amblyopia Any general pathology other than AD with ocular implications
-Inability to perform tear collection
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Patients with AD dementia
Patient ≥ 18 years old with AD at a major stage according to the 2018 NIA-AA criteria (dementia) |
Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers |
|
アクティブコンパレータ:Patients with AD Mild Cognitive Impaiment (MCI)
Patient ≥ 18 years old with AD at a minor stage according to the 2018 NIA-AA criteria (Mild Cognitive Impairment) |
Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers Collection of a blood sample (5 mL) for blood biomarkers analysis. |
|
偽コンパレータ:Healthy controls
Participants ≥ 18 years old with no known central neurological pathology, no cognitive decline, and matched by age (± 2 years) and sex with a patient from AD-MCI group |
Collection of a tear volume of (i) 2 x 5µL using glass microcapillary tubes and (ii) 12µL using Schirmer strips after the instillation of anesthetic eye drops for metabo-lipidomic analysis and multiplexing of protein markers |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concentration of total Tau proteins in basal tears of patients with AD vs healthy volunteers
時間枠:At inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
At inclusion
|
|
Concentration of phosphorylated Tau proteins in basal tears of patients with AD vs healthy volunteers
時間枠:At inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
At inclusion
|
|
Concentration of Amyloid β 1-40 proteins in basal tears of patients with AD vs healthy volunteers
時間枠:At inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
At inclusion
|
|
Concentration of Amyloid β 1-42 in basal tears of patients with AD vs healthy volunteers
時間枠:At inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
At inclusion
|
|
Lipids in basal tears of patients with AD vs healthy volunteers
時間枠:At inclusion
|
Collection of tears (5μL) using a glass micropipette without local anaesthetic. Lipids in tears of patients with AD vs healthy volunteers |
At inclusion
|
|
Metabolites in basal tears of patients with AD vs healthy volunteers
時間枠:At inclusion
|
Collection of tears (5μL) using a glass micropipette without local anaesthetic. Metabolites in tears of patients with AD vs healthy volunteers |
At inclusion
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concentration of total Tau proteins in tears vs plasma and Cerebral spinal fluid (CSF) within patients with AD-MCI
時間枠:At inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
At inclusion
|
|
Concentration of phosphylated Tau proteins in tears vs plasma and Cerebral spinal fluid (CSF) within patients with AD-MCI
時間枠:A inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
A inclusion
|
|
Concentration of Amyloid β 1-40 proteins in tears vs plasma and Cerebral spinal fluid (CSF) within patients with AD-MCI
時間枠:A inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
A inclusion
|
|
Concentration of Amyloid β 1-42 proteins in tears vs plasma and Cerebral spinal fluid (CSF) within patients with AD-MCI
時間枠:A inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
A inclusion
|
|
Lipids in tears vs plasma and Cerebral spinal fluid (CSF) within patients with AD-MCI
時間枠:At inclusion
|
Collection of tears (5μL) using a glass micropipette without local anaesthetic. Identification of lipids in basal tears using liquid chromatography-mass spectrometry. |
At inclusion
|
|
Metabolites in tears vs plasma and Cerebral spinal fluid (CSF) within patients with AD-MCI
時間枠:At inclusion
|
Collection of tears (5μL) using a glass micropipette without local anaesthetic. Identification of metabolites in basal tears using liquid chromatography-mass spectrometry. |
At inclusion
|
|
Concentration of total Tau proteins in basal tears of patients with AD-dementia vs patients with AD-MCI
時間枠:At inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
At inclusion
|
|
Concentration of phosphorylated Tau proteins in basal tears of patients with AD-dementia vs patients with AD-MCI
時間枠:At inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
At inclusion
|
|
Concentration of Amyloid β 1-40 proteins in basal tears of patients with AD-dementia vs patients with AD-MCI
時間枠:At inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
At inclusion
|
|
Concentration of Amyloid β 1-42 proteins in basal tears of patients with AD-dementia vs patients with AD-MCI
時間枠:At inclusion
|
12μL of tears will be collected using Schirmer strips after instillation of an anaesthetic eye drop. A multiplex analysis for the detection of protein of interest |
At inclusion
|
|
Lipids in basal tears of patients with AD-dementia vs patients with AD-MCI
時間枠:At inclusion
|
Collection of tears (5μL) using a glass micropipette without local anaesthetic. Identification of lipids in basal tears using liquid chromatography-mass spectrometry. |
At inclusion
|
|
Metabolites in basal tears of patients with AD-dementia vs patients with AD-MCI
時間枠:At inclusion
|
Collection of tears (5μL) using a glass micropipette without local anaesthetic. Identification of metabolites in basal tears using liquid chromatography-mass spectrometry. |
At inclusion
|
協力者と研究者
捜査官
- スタディディレクター:Victoire LEROY, MD、CHRU de Tours
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- DR240140
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers may obtain access to all deidentified data in COG-EYE on a substantial request.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。